首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Scyb11 |
| Uniprot No | O14625 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-94aa |
| 氨基酸序列 | FPMFKRGRCL CIGPGVKAVK VADIEKASIM YPSNNCDKIE VIITLKENKG QRCLNPKSKQ ARLIIKKVER KNF |
| 预测分子量 | 8.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCYB11(CXCL11)重组蛋白的3篇参考文献示例：
1. **文献名称**：重组人CXCL11的制备及其趋化活性研究
**作者**：李明等
**摘要**：该研究通过原核表达系统成功制备了重组人CXCL11蛋白，并验证其趋化T细胞和NK细胞的能力，为肿瘤免疫治疗研究提供基础。
2. **文献名称**：CXCL11重组蛋白在慢性炎症模型中的调控作用
**作者**：Smith J, et al.
**摘要**：研究发现，重组CXCL11蛋白通过抑制Th1细胞迁移减轻小鼠结肠炎症状，揭示了其在炎症性疾病中的潜在治疗价值。
3. **文献名称**：Structural and functional analysis of SCYB11 in viral infection
**作者**：Chen R, et al.
**摘要**：通过晶体学解析重组SCYB11的三维结构，并证明其与受体CXCR3结合的特性，为抗病毒药物设计提供结构基础。
注：上述文献为示例性质，实际研究中建议通过学术数据库(如PubMed、Web of Science)以“CXCL11 recombinant”或“SCYB11 protein”为关键词检索最新成果。
Scyb11. also known as CXCL11. is a small cytokine belonging to the CXC chemokine family, primarily recognized for its role in immune regulation and inflammatory responses. It is encoded by the *CXCL11* gene in humans and is structurally characterized by conserved cysteine residues (C-X-C motif) that define its functional interactions. This chemokine is strongly induced by interferons (IFN-γ and IFN-β), linking it to Th1-type immune responses and antiviral or antitumor activities.
Recombinant Scyb11 (rScyb11) is produced via genetic engineering, typically using expression systems like *E. coli* or mammalian cells, followed by purification steps to ensure bioactivity. The recombinant form retains the native protein's ability to bind and activate the CXCR3 receptor, which is highly expressed on activated T cells, natural killer (NK) cells, and dendritic cells. This interaction facilitates leukocyte migration to sites of inflammation, modulates immune cell functions, and enhances cytotoxic responses against infected or malignant cells.
Research on Scyb11 highlights its dual role in immunity: it promotes pathogen clearance and tumor suppression but may also contribute to autoimmune disorders or chronic inflammation when dysregulated. Its therapeutic potential is being explored in cancer immunotherapy, particularly in combination with checkpoint inhibitors, to enhance T-cell infiltration into tumors. Additionally, recombinant Scyb11 serves as a critical tool in studying chemokine-receptor signaling, leukocyte trafficking, and inflammatory disease mechanisms. Challenges remain in optimizing its stability and delivery in vivo, but ongoing studies continue to unravel its complex roles in health and disease.
×
